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Abstract: Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase that
is overexpressed and activated in many human cancers. FAK transmits signals to a wide range of
targets through both kinase-dependant and independent mechanism thereby playing essential roles
in cell survival, proliferation, migration and invasion. In the past years, small molecules that inhibit
FAK kinase function have been developed and show reduced cancer progression and metastasis in
several preclinical models. Clinical trials have been conducted and these molecules display limited
adverse effect in patients. FAK contain multiple functional domains and thus exhibit both important
scaffolding functions. In this review, we describe the major FAK interactions relevant in cancer
signalling and discuss how such knowledge provide rational for the development of Protein-Protein
Interactions (PPI) inhibitors.
Keywords: FAK; cancer signalling; PPI inhibitor; FAK inhibitor
1. Search for Inhibitors of Protein-Protein Interaction
1.1. Introduction
During the last two decades, considerable efforts have been made in the understanding of the
molecular mechanisms of diseases. However, at present, only a small portion of proteins (around
400) involved in diseases have been explored as therapeutic targets [1]. Indeed, functional genomic
studies have predicted that 3000–10,000 proteins are implicated in diseases [2]. Currently, therapeutic
targets are primarily G protein-coupled receptors, enzymes, ion channels, transporters and nuclear
receptors. These proteins are considered as easy to target because they have natural ligand-binding
sites for endogenous agonists or substrate. It is therefore not surprising that pharmaceutical companies
have extensively exploited these druggable proteins. However, the number of new drug approvals
is stagnating at around 15–25 per year since five decades and the majority of launched drugs are
derivatives of lead compounds with the same chemical signature [3]. Thus, the challenge in drug design
and discovery is to identify new potential therapeutic targets in order to propose innovative therapies.
Among these potential new targets, protein-protein interactions (PPIs) are of considerable and
growing interest. Indeed, PPIs are critical for many aspects of cell biology and are involved in
physiological as well as pathological processes. However, targeting PPIs with small “drug-like”
molecules is challenging for at least two main reasons. First, the contact surfaces involved in
PPI are large (1500–3000 Å2) compared with those involved in small-molecule-protein interactions
(300–1000 Å2) [4,5]. In PPI, affinity is mostly obtained by a multitude of often weak interactions. It is
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therefore difficult to design a small molecule that could bind tightly because of insufficient interactions.
Second, the contact surfaces are usually flat and often lack the pockets that are characteristic of natural
ligand-protein contact surfaces. Traditional ligand-binding sites are characterized by one or two large
pockets with a typical volume close to 260 Å3 in contrast to PPI, which involve an average of six small
pockets with a pocket volume around 54 Å3 [6]. It is therefore difficult to predict which pocket (s) at
the protein-protein surface contact will be able to bind a small inhibitor, if any.
Despite these challenges, several evidences provide hope for discovering small drug-like
molecules that would target PPI interfaces. Even though the protein-protein interfaces are large,
mutational studies have shown that a small subset of residues involved is essential for high-affinity
binding; they are called hot spots [7]. The disruption of the interactions mediated by these hot spots is
efficient in inhibiting PPIs [8]. Hotspots often comprise side chains of tyrosine, tryptophan and arginine
that all allow adaptive conformational changes to accommodate small molecules as well as strong
hydrogen-bonding potential through nitrogen and oxygen atoms [9]. Traditional high-throughput
screening (HTS), which is particularly suitable for the drug discovery in well-defined “druggable”
pockets, was at present not very successful. This could be explained by the content of compounds
used for screening that are derived mainly from chemistry efforts in pharmaceutical companies.
These chemotypes are dominated by past drug-discovery research on GPCR, enzymes and traditional
druggable targets. However, PPI interfaces strongly differ from druggable well defined binding
pockets and therefore, the discovery of successful inhibitors requires that new chemotypes need to
be included in HTS libraries in order to match to these novel class of target. Indeed, it is believed
that except for close homologues, each protein-protein interface is different, so the chemotypes of
their inhibitors are likely to be more isolated in chemical space. Computational modelling methods in
combination with high-resolution X-ray crystal structures of protein complexes seriously improved the
prediction of relevant small-molecule binding pockets on a protein-protein interface [10]. Additionally,
advances in fragment-based lead discovery allow the rapid probing of the protein surface for small
chemical fragments binding sites and therefore addresses the druggability issue [11]. It is possible that
evaluating the structure activity relationship of compounds by nuclear magnetic resonance (NMR)
as in fragment-based screening will be more successful than HTS when applied to PPI. Full ligand
screening has already been used to find an inhibitor of Keap1/Nrf2 interaction able to initiate an
anti-oxidant and anti-inflammatory response [12]. Furthermore, fragment-based methods have allowed
discovering an inhibitor of STAT3 dimerization, which inhibits nuclear translocation of the protein and
the transcription of pro-carcinogenic genes [13].
1.2. Successful Examples
Successful examples of PPI inhibitors have been reported in distinct biological pathways. One of
those and probably the best-characterized are the inhibitors of the interaction between p53 and human
protein double minute 2 (HDM2). MDM2 (the mouse homologue of HDM2), which is an ubiquitin E3
ligase was initially found to binds to the tumour suppression protein p53 leading to its proteasomal
degradation [14]. p53 is inactivated by mutation or deletion of its gene in nearly 50% of human
cancers. In the other 50% displaying wild-type p53, its tumour suppression function can be altered
by several distinct mechanisms. One major inhibitory mechanism is mediated by the interaction
between MDM2 and p53. This interaction has been mapped to the first 120 amino acid residues in
the N-terminal domain of HDM2 and the 30 first amino acid residues in the N-terminal domain of
p53. High-resolution crystal structure of MDM2 complexed with residues 15–29 of p53 was solved in
1996 [15] and reveals that p53/MDM2 interaction is mediated by a well-defined hydrophobic surface
in MDM2 and three key hydrophobic residues in p53 (Phe19, Trp23 and Leu26) [15]. In search of
inhibitors, the first class of potent and specific small MDM2 inhibitors were identified by HTS at
Hoffmann-La Roche. These tetra-substituted imidazole inhibitors were named Nutlins. Nutlin-3,
one of the most potent of these small molecules was reported to bind to MDM2 with IC50 = 90 nM and
showed antitumour activity against xenografts in vivo [16]. Using NMR spectroscopy, Nutlin-3 was
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shown to insert its aromatic moieties into the same hotspot pockets in MDM2 where p53 binds [17].
Structure-activity relationship studies lead to the discovery of a refined Nutlin-3-derived compound,
RG7112, which is the first MDM2 inhibitor advanced into clinical trials for the treatment of several
human cancers [18]. RG7112 effectively binds to MDM2 with IC50 = 18 nM and inhibits the growth
of cancer cell lines with wild-type p53 in vitro with IC50 = 0.18–2.2 µM. Moreover, it demonstrated
good selectivity over cancer cell lines with p53 mutation (IC50 = 5.7–20.3 µM). Clinical evaluation
of RG7112 after oral administration in phase I clinical trials have shown that the molecule is able to
activate p53 signalling in human tumours leading to apoptosis [18]. These studies have provided a
proof of concept that PPI inhibitors are efficient at the clinical level. However, several patients treated
by RG7112 had severe adverse effects including neutropenia and thrombopenia. This haematological
toxicity has prompted the development of a more selective compound, RG-7388 (Idasanutlin) actually
in phase III of the clinical trial [19]. Several other MDM2 inhibitors are now making their way through
clinical trials including AMG232 developed by Amgen (phase I/II) or MK-8242 developed by Merck
(phase I) [20]. Their antitumoral activities are tested as single agents or in combination with traditional
chemotherapeutic agents.
Another example of PPI inhibitors is small inhibitors of the Bcl-2 family in clinical trials especially
for the treatment of patients with lymphoid malignancies. The Bcl-2 (B-cell lymphoma 2) family
contains important regulators of apoptosis. These proteins govern mitochondrial outer-membrane
permeabilization and form homodimers or heterodimers with other family members to mediate either
a pro-apoptotic or a pro-survival signal. The effect of pro-apoptotic proteins Bak and Bax are blocked
by the interaction with anti-apoptotic partners such as Bcl-2 and Bcl-X. This interaction is mediated
by a hydrophobic BH3 domain in pro-apoptotic protein containing four key hydrophobic residues
(Leu 59, Leu 63, Ile 66 and Leu 70) [21]. Disrupting this interaction by binding the anti-apoptotic
Bcl-2 family proteins with small molecules BH3 mimetics induce apoptosis of cancer cells [22]. Abbott
laboratories by using N heteronuclear single quantum coherence (HSQC) protein NMR, has developed
Bcl-2 family inhibitors such as ABT-263 (Navitoclax). This compound binds Bcl-2 protein in vitro
with subnanomolar affinities and inhibits tumour growth of chronic lymphocytic leukaemia (CLL)
when combined with rituximab in phase II of clinical trial. However, navitoclax was found to induce
thrombopenia by binding the anti-apoptotic Bcl-X protein with a similar affinity to Bcl-2 protein. Since
the disclosure of navitoclax, several monoselective inhibitors of Bcl-2 has been developed such as
venetoclax [23,24]. Venetoclax was shown to selectively bind Bcl-2 with high affinity and to induce
apoptosis by Bax-Bak signalling. Its efficiency was demonstrated in a human xenograft model of
B cell lymphoma and more recently in phase I/II of human clinical trial [24] as single agents or in
combination with traditional chemotherapeutic agents. This new class of Bcl-2 inhibitor reduces
thrombocytopenia risk associated with the inhibition of Blc-X while conferring a rapid reduction of
tumour in CLL patients.
Thus, PPI inhibitors may represent an interesting alternative to target protein kinases. Indeed, the
majority of reported protein kinase inhibitors are ATP-binding competitors which bind to the active
kinase conformation (type I inhibitors) resulting in often limited kinase selectivity due to the high degree
of conservation within the ATP-site. Searching for competitive inhibitors rather than ATP-competitive
inhibitors may be a more rational approach. At present, more than 1500 ATP-dependent enzymes
have been identified with 420 Ser/Thr kinases and 90 Tyr Kinases. Moreover, the high intracellular
ATP concentrations necessitate high intracellular concentrations (µM) of the inhibitor to effectively
inhibit the target, even when the affinity of the inhibitor is in the nanomolar range [25]. On the
other hand, PPI inhibitors frequently have subnanomolar affinity to the target and their efficiency
has already been proven at this concentration in many cases. Thus, selectivity of these inhibitors
may be better than kinase inhibitors that compete with ATP in the substrate-binding site. Moreover,
inhibition of kinase activity does not alter protein scaffold properties and subsequent signalling
pathways. PPI can be targeted with small molecules that would have a pharmacokinetic profile that
is different from the current known PPI inhibitors. Currently, the majority of small molecules in
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clinical trials are orally available drugs despite of their high molecule weight and hydrophobic clusters.
However, PPI inhibitors design is challenging and requires a perfect understanding of the structure
activity relationship.
2. FAK Structure and Interaction
More than twenty years ago, FAK was first described as a substrate of the oncogene product of
the sarcoma virus (v-Src) and as a protein highly phosphorylated upon clustering of Integrins at focal
adhesions [26–28]. Soon after, the group of William Cance at the University of North Carolina found
an increase in FAK mRNA in invasive and metastatic human tissues [29]. Subsequently, analysis of
FAK protein expression in a variety of human tumours revealed increased levels of FAK that correlated
with the invasive potential of these tumours [30]. This lead to intensive research for the mechanisms of
FAK activation and the signalling pathways regulated by the kinase. FAK is a ubiquitously expressed
non-receptor cytoplasmic tyrosine kinase composed of an N-terminal FERM (band 4.1, ezrin, radixin,
moesin homology) domain, a central kinase domain, several proline-rich domains and a C-terminal
focal adhesion targeting (FAT) domain (Figure 1). FAK is primary implicated in the regulation of
signals initiated at sites of Integrin mediated cell adhesion to the extra-cellular matrix as well as signals
triggered upon growth factor receptors activation [31]. The first experimental evidence implicating
FAK in tumour formation and progression was obtained by using conditional knock-out mice with
selective fak deletion in the epidermis [32]. This proof of concept experiment led to the development of
strategies aimed at inhibiting FAK with the hope to reduce tumour progression. Thus, the development
of FAK antagonists, as anti-cancer therapy, led to several small inhibitors of FAK kinase function that
are currently undergoing clinical trials.
Nevertheless, besides its kinase function, FAK possess also scaffolding functions that are highly
relevant in cancer signalling [33]. Indeed, according to the Biological General Repository for Interaction
Datasets (BioGRID) [34,35], FAK is involved in none less than 235 interactions. Nevertheless, some of
these interactions are redundant because they were characterized via different methods and by different
laboratories. For example, Paxillin both interacts with the FAT domain of FAK and is a substrate for
its kinase activity. Thus, the total number of unique FAK interactions identified until now is rather
125 (Figure 1). The BioGRID data base considers as an interaction any direct physical binding of two
proteins, co-existence in a stable complex and genetic interaction. Therefore, the term interaction does
not necessary involve a physical interaction between two proteins as these interactions are recorded
using various techniques including affinity capture-MS, affinity capture-Western, biochemical activity,
co-fractionation, co-purification, FRET or two-hybrid. For example, the affinity capture method
identifies an interaction when a protein is affinity captured from cell extracts by an antibody and the
associated partner identified either by mass spectroscopy or by Western blot. Thus, for FAK, some
interactions were identified by the two-hybrid system while many others were characterized by the
affinity capture-Western method and therefore may also be indirect as part of a signalling complex.
Interactions identified by high-throughput two-hybrid systems need to be further characterized in
order to establish their biological effect on a defined system and thus will not be fully addressed in
this study. In this review, we will rather focus on direct FAK interactions with a particular interest for
those involved in cancer initiation and progression. These interactions and their consequences on FAK
activation and signalling will be described in details and we will examine how the knowledge of the
structural motifs involved in these interactions could be the basis for development of PPI inhibitors.
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Figure 1. The main structure domains of FAK. Important sites of tyrosine phosphorylation are also
indicated. Graphical network of FAK protein interactions identified by BioGRID based on a compilation
of publications referring to protein and genetic interactions. Circles with layers closest to the centre are
more highly connected.
3. FAK Structural Determinant for the Search of Potent FAK Inhibitors
3.1. Major Interactions t the FERM Dom in
3.1.1. FAK Interaction with Growth Factor Receptors and Mechanism of FAK Activation
The best characterized mechanism that promotes FAK activation involves Integrin receptor
clustering upon cell binding to the extracellular matrix which has been shown to involve binding of the
β Integrin cytoplasmic domain to FAK [27,36,37]. Fur her analysis of Integrin-FAK interactions revealed
that the cytoplasmic tail of the β1 Integrin directly stimulates FAK activity in vitro, this activity being
increased after deletion of the FERM domain of FAK suggesting a mechanism of FAK autoinhibition [38].
Recently, the β4 Integrin-FAK interaction was mapped to 11-amino-acid region ahead of the FAK
Tyr397 site [39]. FERM domains usu lly promote the coupling of cytoskeletal str ctures o the plasma
membrane. In the case of FAK, recent studies have shown that the regulation of FAK activity entails
an intramolecular association of the FERM domain with the kinase domain, which then blocks the
accessibility of the Tyr397, the autophosphorylation site. Indeed, the crystal structure of a FAK fragment
containing the FERM domain and the kinase domain in its auto-inhibited form reveals that this
interaction requires the F2 lobe of the FERM domain notably the residues Y180 and M183 and the
c-lobe of the kinase domain centred on F596 [40]. This mechanism of action implies that lipid-protein
and/or protein-protein interactions in the FERM domain are necessary to release the FERM-kinase
interaction (Figure 2). Thus, many components able to induce FERM-kinase domain opening have been
proposed which include Phosphatidylinositol-4,5-bisphosphate (PtdIns (4,5) P2 [41] the tetraspanin
TM4SF5 [42] and growth factor receptors. Among the latter both PDGFR, EGFR, IGF-1R, c-Met and
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RET were shown to form a complex with the FERM domain of FAK [31,43–45], thus suggesting that
the resulting increases in FAK activation, may be due to the relief of the FERM-kinase auto-inhibition.
In the case of RET kinase, a transactivation mechanism has been highlighted which involves reciprocal
phosphorylation of FAK Tyr575/576 by RET and RET Tyr905/1062 by FAK. Recently, HER2 was
shown to directly interact with the FAK-FERM-F1 lobe thereby promoting phosphorylation of FAK
Tyr 397 [46]. On the other hand, c-Met promotes FAK phosphorylation at Tyr194 leading to FAK
activation. Constitutive activation of FAK by replacement of Tyr194 with the phosphomimetic E194
can be overcome by mutations of the basic patch KAKTLRK of the F2 lobe of the FERM domain,
indicating that the interactions between the phosphorylated Tyr194 and these basic residues may
allow FAK activation through relief of its autoinhibition [47]. Consequently, the addition of HGF
stimulates invasion of MDCK cells through Matrigel. VEGF also stimulates FAK activation leading
to the association of the cytoplasmic tail of VE cadherin with the FAK FERM domain thus enabling
β-catenin phosphorylation to promote junctional disassembly and vascular permeability. As the VEGF
dependency of FAK activation is lost upon Y180A/M183A mutation it is believed that in endothelial
cells, VEGF activates FAK in a conformation-dependent manner [48]. Early experiments have also
demonstrated a role of the FAK-Ezrin interaction in the control of FAK activity as in kidney-derived
epithelial cells, ezrin promoted FAK phosphorylation at Tyr-397. Mapping experiments showed that
FAK amino acids 1–376 were required for optimal Ezrin binding [49].
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Interactions References
Integrin, PIP2, Tetraspanin [27,37,39,41,42,50,51]
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Cadherin, Ezrin, Dynamin [48,49,52]
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Figure 2. Structure of the FERM domain of FAK from the protein databank (accession code
2AL6). The FERM domain displays three lobes, F1, F2 and F3. The structure includes the Tyr397
auto-phosphorylation site which is located between the FERM and kinase domain. In the F2 lobe, residues
belonging to basic patches important for FAK activation are highlighted and their side chains coloured
in green. The auto-inhibitory interaction implicates residues from the F2 lobe of the FERM domain and
C lobe from the kinase domain. The Trp266 implicated in FERM-FERM interaction necessary for FAK
dimerization is also highlighted. Proteins associating with the FERM domain are shown in the table.
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Using a FRET-based biosensor for monitoring FAK activation it was also confirmed that PIP2
triggers a change in FAK conformation state which likely represents unbinding of the FERM-kinase
domain [50]. However, PIP2 has been shown to be necessary for FAK clustering at the membrane and
partial opening of FAK conformation without complete release of auto-inhibitory interactions [51].
Thus, it remains possible that increased PIP2 levels simply induce clustering of FAK molecules
necessary for the FAK trans-phosphorylation. In this case, other mechanisms such as FAK dimerization
mediated by traction force or FERM-FERM interactions would be necessary to release the closed
FERM-kinase conformation state. Force-mediated FAK activation has been shown to involve a basic
patch in the FERM domain able to prevent FAK inhibition induced by an interaction between FERM
domain acidic sites and Myosin II [63]. Moreover, FAK activation by dimerization which has been
first described in 2002 [64] require an intermolecular FERM-FERM interaction around residue W266
stabilized by the FAT (Focal Adhesion Targeting) binding to a basic patch K216AKTLRK located in the
FERM F2 lobe [65]. The FERM domain is also involved in direct FAK binding to Integrin-containing
endosomes thereby regulating adhesion induced FAK activation and cancer related processes such as
anchorage-independent growth [66]. This report established an unprecedented FAK activation pathway
distinct from the signalling role of Integrin/FAK complexes at FAs. Nevertheless, the relationship
between FAK and the endocytic and membrane trafficking processes was first described by Gundersen’s
group, who found an interaction between FAK and dynamin at FAs during forced FA disassembly [52].
Latter it was shown that dynamin is specifically recruited at FAs by a direct interaction with the FERM
domain of FAK thus allowing dynamin phosphorylation at Tyr 231 by Src [67].
Other mechanisms of FAK autoinhibition have also been unveiled. First, based on early structural
data on the FERM domain together with different linker segments, the Tyr397 site was shown to be
inaccessible because of an interaction with the F1 lobe of the FERM domain and inhibition of Src binding
due to sequestration of the SH3 binding site via an intramolecular interaction with the F3 lobe [68].
Second, it was recently reported that relief of FERM autoinhibition can be provided by changes in pHi
which mediated deprotonation of the H58 residue of the FERM domain and subsequent conformational
changes that modulating the accessibility of Tyr397 [69]. In the autoinhibited conformation, it is
possible that the FAK FERM domain may also bind to the actin nucleating protein Arp3 and promotes
the recruitment of the Arp2/3 complex to nascent adhesions in a kinase-independent manner [70].
As FAK is needed for nascent adhesion assembly, this complex could be implicated in the transition of
nascent adhesion into FA. This interaction implies FAK K38 a residue previously implicated in FAK
activation [53] suggesting that FAK binding to Arp2–3 may be one element for the release of FAK
auto-inhibition. This FAK/Arp3 interaction has been recently shown to be involved in haptotaxis [54].
3.1.2. FAK Control of Cell Polarity and Migration
Several mechanisms seem to be implicated in the control of wound-induced cell polarity. Indeed,
it was first described that FAK directly interact and phosphorylate the actin regulatory protein N-WASP
thereby promoting cell migration [55]. Integrin-mediated FAK phosphorylation at Tyr397 creates a
binding site for p120RasGAP which allows FAK to subsequently phosphorylate p190A thus creating a
molecular complex that regulate Golgi orientation and cell polarization [71]. Latter, other experiments
indicated that another complex composed of FAK, RACK1 and PDE4D5 located at nascent adhesion is
also involved in Golgi orientation and direction sensing. The interaction of FAK with RACK implicates
residues 139–140 located in the FERM domain and mutation of these residues lead to impaired nascent
adhesion formation, Golgi reorientation, polarization and chemotactic invasion in squamous cell
carcinoma [56]. Moreover, a peptide disrupting RACK1-PDE4D5 binding mimics the effect on Golgi
re-orientation. This FAK/RACK1/PDE4D5 complex likely signals to the guanine nucleotide exchange
factor EPAC, which in turn activates its small GTPase target Rap1. Interestingly, this signalling
complex has been shown to mediate cell invasion in BRAF-mutated melanoma suggesting a link
between polarity efficiency and cell invasiveness [72]. The transcription factor Nanog also mediate cell
invasion via direct binding to the N-terminal domain of FAK with subsequent increased formation
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of filopodia/lamellipodia [58]. Finally, FAK is also able to activate ETK, a member of the Bruton’s
tyrosine kinase (Btk), via interaction of the F1 sub-domain of FERM and the PH domain of ETK.
This interaction is involved in the regulation of Integrin-mediated endothelial and metastatic carcinoma
cell migration [57].
3.1.3. FAK Functions in the Nucleus
The FERM domain of FAK contain different elements such as nuclear localization signals (NLS)
and nuclear export signals (NES) that regulate the shuttling of FAK between the nucleus and FA.
In the F2 lobe, beside the 216KAKTLRK222 basic patch which mediates interaction with other proteins,
another partially overlapping surface exposed basic patch involving K190/191, K216/218, R221 and
K222 has been shown to mediate FAK localisation to the nucleus. This raised the intriguing possibility
that in the absence of FAK activation signal involving binding of c-Met, PIP2 or other molecules to
these basic residues, FAK will be mainly located to the nucleus due to unmasking of the NLS signal.
Besides, another basic patch namely R177/178 located in the F2 lobe is also consistent with NLS
signal activity [59]. Interestingly, FAK can be post-translationally modified by addition of a small
ubiquitin-related modifier (SUMO) at the Lys152 residue via PIAS1 (Protein Inhibitor of Activated
STAT1) binding to the FERM domain [60]. Sumoylation is often associated with nuclear import and
sumoylated FAK present in the nuclear fraction is associated with increased FAK activity.
Normal cells require adhesion to the ECM in order to survive and grow a process that is
dependent on FAK activation. Indeed, many reports have shown that inhibition of FAK leads
to the onset of apoptosis [73,74]. Besides, FAK is over-expressed in many cancer cells [75] and a
hallmark of the tumourigenesis process is the resistance to anoikis a form of apoptosis induced by
the loss of contact to the ECM. Survival signals can be transduced either by the activation of the
PI-3K/AKT pathway, cell cycle progression through cyclin D1 or inhibition of apoptotic pathways such
as caspase and FADD-dependent pathways or p53 signalization. Receptor-Interaction Protein (RIP) is
a serine/threonine kinase that contains a death domain and associates with the death receptor complex
to provide apoptotic signals. This signal could be inhibited via direct interaction of the N-terminal
domain of FAK with the death domain of RIP [61]. Moreover, early studies demonstrated that FAK
transduces survival signals from the ECM via inhibition of p53 as a consequence of direct interaction
between the N-terminal domain of FAK and the N-terminal domain of p53 [62]. Later, it was shown
that FAK-meditated survival requires the F2 lobe of the FERM domain for nuclear localization of FAK,
the F1 lobe for binding to p53 and the F3 lobe for interactions with Mdm2 [59]. This mechanism implies
ubiquitination of p53 and Mdm2-mediated proteasomal degradation thus keeping p53 at low levels to
facilitate cell survival. At this time, this was one of the first kinase-independent roles of FAK described
which requires only the scaffolding function of FAK.
3.1.4. Inhibitor of FERM Interactions
The search for inhibitors of PPIs can be made by selectively targeting mechanisms that modulate
the kinase activity or specific interactions with known regulators of cancer-related pathways. For the
first purpose, one should target protein-protein interactions that play a role in the regulation of kinase
activity in order to achieve targeting specificity. In this aim, a protein pharmacophore model for
the FAK-related kinase Pyk2 F3 FERM domain was recently generated and served as a template for
the screening of the LeadQuest database. This led to the identification of a small compound that
directly bind to the Pyk2 FERM domain and inhibited the Pyk2-stimulated glioma cell migration [76].
Nevertheless, because the survival pathway is critical for cancer progression inhibiting FAK/p53
interactions using PPIs could therefore represent an efficient alternative of classical kinase inhibitors.
The search of PPI inhibitors to reduce FAK activity has been pioneered by the group of William Cance
at the Roswell Park Cancer Institute in Buffalo. They first described a sequence of 7-amino-acid
residues in the N-terminal proline-rich domain of human p53 necessary for FAK binding and show
that a peptide containing these residues together with a TAT sequence for cell penetration was able to
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reduce viability of breast and human colon carcinoma cell lines [77]. Having validated this interaction
as a potential therapeutic target, they performed computer modelling of the p53 peptide containing
the 7 amino acid sequence, docked it into the three-dimensional structure of the FERM domain
of FAK involved in the interaction with p53 and screened small molecules from different libraries
for docking into the FAK-p53 pocket [78]. Several small compounds were selected and notably
the compound 1-benzyl-15,3,5,7-tetraazatricyclo [3.3.1.1~3,7~] decane, named Roslin2 were able to
reactivate p53 in colon cancer cells both in vitro and in-vivo and to sensitize cancer cells to doxorubicin
and 5-fluorouracil.
Another successful example came from the same group targeting the FAK-Mdm-2 interaction.
Mdm-2 is a p53 target involved in p53 proteasomal degradation which was found to bind FAK via
the F3 lobe of the FERM domain [59]. Using the structures of the FAK FERM domain and Mdm-2,
macromolecular techniques were used to model the FAK-FERM interaction which serves as a template
for the virtual screening of 200,000 small molecule compounds from NCI database. This strategy
helped them to identify a 5’-O-Tritylthymidine compound called M13 that significantly decrease
viability in different cancer cells [79]. Several other protein-binding sites have been identified in the
FERM domain. For example, pharmacological inhibition of FAK-mediated FAK localisation in the
nucleus promotes anti-inflammatory properties via an interaction between the FERM domain of FAK
and GATA4 thus preventing cytokine-stimulated VCAM-1 transcription [80]. Moreover, in addition to
the known effect of Nanog, a homeobox transcription factor, on FAK transcription, Nanog also directly
bind the N-terminal domain of FAK leading to Nanog phosphorylation which in term lead to altered
cancer cell filopodia and lamellipodia formation [58].
The interaction between FAK and IGF-1R was also partially characterized. It appears that this
interaction encompasses FAK amino-acid 127–243 and the N-terminal part of IGF-1R [81]. Using the
strategy described above, modelling and targeting the FAK-IGF-1R interaction led to the identification
the lead compound INT2-31 [81]. This compound was shown to effectively disrupt FAK/IGF-1R
interaction in melanoma leading to reduce cell viability and proliferation and to the induction of cell
arrest and apoptosis. Importantly, in-vivo in tumour xenografts, the compound effectively decreased
AKT signalling, resulting in significant melanoma tumour regression [82].
3.2. Major Interactions at the Kinase Domain
3.2.1. Role of Tyr397 in FAK Catalytic Activity and Interactions with Binding Partners
Tyr397, which is located between the FERM and the kinase domain, is the major FAK activation
site (Figure 3). FAK phosphorylation at the Tyr397 residue occurs via both intra and intermolecular
processes [64,83]. Early studies have shown that mutation of Tyr397 to Phe altered cell adhesion and
leads to reduced focal adhesion turn-over and cell motility in many cell types [84,85]. Phosphorylation
of FAK tyr397 creates a motif that is recognize by Src family kinases thereby inducing several
downstream signalling pathways [86]. Depending on the cell type, Src family kinases phosphorylate
other tyrosine residues namely Tyr407, Tyr576, Tyr577 in the kinase domain, Tyr 861 in the junction
between the kinase and FAT domain and Tyr925 in the FAT domain [87–89]. Tyr407 negatively
regulates FAK activity whereas Tyr567 and 577 are necessary for full catalytic activity of the kinase
function [87,90]. In addition to autophosphorylation, FAK is implicated in the phosphorylation of
several other FA associated proteins including Paxillin [91] and p130CAS [92] although it is not entirely
clear whether it is the kinase function of FAK or Src kinase in complex with FAK which phosphorylates
the downstream substrates. Paxillin and p130CAS has both been implicated in the regulation of
migration and invasion pathways. Indeed, cell motility is dependent on the ability of FAK/Paxillin to
control the fine spatiotemporal regulation of FA turn-over [93]. Thus, overexpressing Paxillin that is
mutated at FAK phosphorylation sites inhibits the turnover of focal contacts and cell motility. On the
other hand, the p130CAS/Rac1 pathway has been rather implicated in lamellipodia and invadopodia
formation and thus in mechanisms underlying cell invasion [94].
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FAK phosphorylation at Tyr397 and FAK activation is also important in tumour-associated
endothelial cells where it regulates endothelial cell motility, angiogenesis, endothelial and cell
sprouting [48,106–108]. Thus, besides promoting p osphorylation of FA prot ins, FAK can be also
localized at adherent junc ions in endothelial cells where, upon VEGF acti ation, FAK phosphorylate
directly β cate in at Y142 [48] and indirectly, via Src activation, VE cadherin at Y658 [109]. This has
important implications for the metastatic process as this lead to disruption of β-catenin-VEcadherin
interactions thereby altering endothelial barrier function and increasing vascular permeability.
Localised increases in vascular permeability constitute preferential discrete sites for cancer cell homing
due in part to endothelial FAK-mediated expression of E-selectin [110].
The majority of FAK binding partners at the kinase domain involved the binding of
SH2-containing proteins to FAK phosphorylated at Tyr397 which includes Src [95] but also PI3K [96],
phospholipase Cγ (PLCγ) [97], growth-factor-receptor-bound protein-7 (GRB7) [98], p120 RasGAP [71]
and the suppressor of cytokine signalling, (SOCS) [101]. Upon binding to phosphorylated FAK
at Tyr397, increased PLCγ1 enzymatic activity was observed [97] which may be needed for
calcium-dependent FA disassembly [111,112], while Grb7 binding induced also cell motility, a process
that require FAK-mediated Grb7 phosphorylation [102]. FAK promote also cancer progression by
activating the oncogenic Ras pathway. Negative regulators of Ras, include p120RasGAP, a GTPase
activating protein, which associates directly with Ras and promotes hydrolysis of the bound GTP,
thereby inhibiting Ras activity. In malignant astrocytoma, it was reported that overexpression of FAK
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promote FAK association with p120RasGAP thereby promoting Ras activity through a competitive
inhibition [103]. This association involves Tyr397 as shown by mutation analysis. FAK association with
p120RasGAP also facilitates FAK-mediated phosphorylation of p190RhoGAP that regulates polarity
in migrating cells [71]. Autophosphorylation of FAK at Tyr 397 may also provide binding sites for
proteins that negatively regulate FAK activity. Indeed, SOCS proteins presumably bind FAK to Tyr397
and both the Src homology 2 (SH2) domain and the kinase inhibitory region domains of the SOCS
proteins contribute to SOCS binding to FAK [101]. This led to the inhibition of FAK kinase activity and
to the polyubiquitination and degradation of FAK. Another example of negative regulation of FAK is
represented by the binding of FIP200 (FAK family interacting protein of 200 kDa) to the kinase domain
of FAK which regulate cell cycle progression [105]. Finally, the Phosphatase and Tensin Homolog
(PTEN) tumour suppressor interact with FAK in a FAK Tyr397 dependent manner and reduces the
phosphorylation at this site thereby reducing cell migration and invasion processes [99,100].
3.2.2. FAK Inhibitors: Targeting the ATP Binding Site
FAK phosphorylation and activation drives many cancer-related processes. Therefore, based on
this knowledge, two strategies can be developed to inhibit FAK function in cancer cells. The first is to
inhibit the kinase function of FAK and the second to alter Src binding to FAK because this event is at the
basis of the full FAK kinase activity. Pharmacological companies like Novartis or Pfizer have developed
several kinase inhibitors of FAK which are almost all small ATP-competitive molecules. One of the
first compounds developed was TAE-226 which exhibit nanomolar inhibitory activity toward FAK but
inhibit also insulin-like growth factor-I receptor kinase [113,114]. In vitro, this compound prevented
cell invasion through Matrigel, reduced cell proliferation, increased apoptosis and interestingly, it also
enhanced docetaxel-mediated growth inhibition [115]. In vivo, the therapeutic efficacy of TAE-226
was related to induction of apoptosis of tumour-associated endothelial cells and reduction of tumour
cell proliferation and microvessel density. The crystal structure of the kinase domain of FAK in
complex with this molecule revealed that the DFG motif adopts a helical conformation which is
stabilized by interactions with TAE-226 [116]. Nevertheless, despite substantial selectivity due to
this conformation, the development of this molecule was later abandoned due to off-target effects.
PND-1186 is another FAK inhibitor that targets the ATP-binding site but displays also inhibition
against FLT-3 and ACK1 [117]. This compound, now named VS-4718, is on phase I clinical trials alone
for patient with metastatic cancer or in combination with paclitaxel and Gemcitabine for patient with
pancreatic cancer. At the same time, Pfizer developed PF-271 a compound that displays nanomolar
inhibitory activity toward FAK and Pyk-2 but show high selectivity against a broad range of other
kinases [118]. In multiple human xenograft models this compound display dose dependent antitumor
efficacy. It should be noted that in pancreatic ductal adenocarcinoma, PF-271 inhibit cell migration
in tumour cells but had no effect on cell proliferation at doses 10 times higher than those required
to inhibit FAK catalytic activity and migration/invasion processes [119]. Remarkably, in a phase I
clinical trial study, PF-271 was reported to be safe and well tolerated up to 125 mg twice-per-day
and show significant stabilisation of tumour progression in some patients [120]. On the other hand,
PF-228 another highly selective FAK inhibitor developed by Pfizer, inhibited both chemotactic and
haptotactic cell migration in many cell lines but did not inhibit cell proliferation or induce apoptosis at
similar concentrations [121]. GlaxoSmithKline developed also a FAK inhibitor named GSK2256098
that, in early studies, displayed minor clinical responses in mesothelioma subjects. However, based
on recent work indicating that anti-cancer therapy using selective BRAF inhibitors may activate FAK
pathway [122,123], GSK2256098 was also tested in combination with the MEK inhibitor trametinib in a
Phase Ib study in subjects with advanced solid tumours and in combination with the frizzled class
receptor (SMO) inhibitor vismodegib in a phase II study in patients with progressive meningiomas
harbouring mutations in SMO or NF2. Although the second study is still on-going the first one was
ended because it did not demonstrate improved efficacy in subjects treated with the combination
of GSK2256098 plus trametinib compared to that observed with GSK2256098 monotherapy Finally,
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the late generation kinase inhibitor PF-04554878, now named VS-6063, was reported to stabilize
some patients with colorectal or ovarian tumours in phase I clinical trial and is actually tested in the
phase I/Ia study in combination with the anti-PD-1 Pembrolizumab for patients with advanced solid
malignancies, in a phase I/Ib study in combination with placlitaxel for patients with advanced ovarian
cancer and in two phase II studies, one for patients with KRAS mutant non-small cell lung cancer
and one for subjects with malignant pleural mesothelioma based on their Merlin status. Moreover,
with the idea of fighting cancer therapeutic resistance, a triple combination of VS-6063, carboplatin
and paclitaxel is currently tested in a phase I/II clinical trial named ROCKIF (Re-sensitization of
Carboplatin-resistant Ovarian Cancer with Kinase Inhibition of FAK) for the treatment of patients
with ovarian cancer. Taken together, these results suggest that targeting the FAK kinase activity
with new generation FAK inhibitors may be promising drug especially when added in combinatorial
therapies. Although the selectivity is a well-known problem of many competitive inhibitors of the
ATP binding site, in the case of FAK inhibiting the closely related kinase Pyk2 may be useful as lessons
from FAK−/− cells have shown increased Pyk2 activity due to compensatory effect. However, several
reports suggest that although FAK kinase activity is necessary for cell motility, it may be not essential
for cell proliferation and survival. Indeed, as already mentioned, these later effects are most certainly
mediated by the FERM domain of FAK through regulation of p53 and the Receptor-Interaction Protein.
3.2.3. Inhibiting FAK P-Tyr Binding to SH2-Containing Protein
To avoid selectivity problems typically found with competitive inhibitors of the ATP binding site,
inhibiting the scaffolding function of FAK with the use of PPI inhibitors can be an attractive alternative
approach. Specific interactions between SH2 domain-containing proteins and their phosphotyrosine
counterparts play a significant role in tyrosine kinase signalling pathways. Thus, blocking the
interaction between SH2 domain and its binding protein may inhibit overactive signalling pathways
in cancer cells. For example, using structure-based virtual screening of the National Cancer Institute
chemical libraries, small inhibitors of Stat3, targeting the Stat3 SH2 domain bound to a Stat3
phosphotyrosine peptide, were discovered [124]. In the case of FAK, with a similar strategy to the one
used to characterize Roslin2 and M13, Vita Golubovskaya and her colleagues at Buffalo used computer
modelling together with in-silico screening to target the FAK Y397 site and identify two compounds,
Y11 and Y15 which display high inhibition of FAK autophosphorylation. As described previously Y397,
upon phosphorylation, is involve in FAK interactions with Src, PI3K and some other SH2-containing
proteins. Therefore, it is expected that such compounds would alter apoptosis and migration/invasion
pathways. Indeed in-vitro, Y11 dose-dependently decreased viability, adhesion and clonogenicity in
colon and breast cancer cell lines while significantly reducing tumour growth in a colon cancer cell
mouse xenograft model [125]. Moreover, in in-vivo models of both colon cancer and glioblastoma,
Y15 display synergy with 5-FU and temozolomide chemotherapy respectively [126,127]. Finally, in early
preclinical studies investigating the pharmacokinetic profile, Y15 did not display toxic effect at doses
effective to promote anti- tumoural results. Therefore, altogether, although the selectivity of these
compounds has to be clearly evaluated, the use PPI inhibitors to target FAK-dependent pathways
seem quite promising.
3.3. Major Interactions at the Prolin-Rich Domains
3.3.1. Role of the FAK PR Domain in the Invasion Pathway
FAK contains three prolin-rich (PR) domains mediating many protein interactions (Table 1):
PR1 located within the N-terminal domain between the FERM and the kinase domain surrounding
Pro371/374; PR2 and 3 located both into the C-terminal domain between the kinase and the FAT
domain and surrounding Pro712/715/718 and Pro875/878/881, respectively. PR1 domain is involved
in the interaction with Trio a GEF protein called Trio that regulates FAK activity, focal adhesion
dynamics and the cytoskeleton organization [128]. The PR2 domain is involved essentially in the
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Src/p130Cas-mediated migration and invasion processes. Thus, both Tyr397 and the PR2 domain of
FAK are necessary for Src targeting and activation at FAs [129]. It should be also noted that the same
pattern of interaction has been observed for PI3K where, although many data indicate interactions
between its SH2 domain with FAK phosphorylated at Tyr397, the SH3 domain of the p85 units is also
interacting with the PR domain of FAK [130]. Proteins of the CAS (Crk-associated substrate) family act
essentially as scaffolds to regulate the formation of protein complexes controlling different processes
such as migration, differentiation, cell cycle and apoptosis. p130Cas has been shown to be a component
of the Integrin signalling machinery involved in cell motility. The role of FAK in the targeting and
phosphorylation of p130Cas has been a matter of controversy. Indeed, the SH3 domain of p130Cas
has been shown to be either essential [131] or not [132] to the targeting of p130Cas to FAs. Because
p130Cas exists at FAs in a macromolecular complex with FAK and Src, both of which sharing PR
domain and tyrosine kinase activity, the relative role of FAK and Src in addressing and phosphorylating
p130Cas are difficult to assess. One model postulates that FAK autophosphorylation at Tyr397 allows
the recruitment of Src via its SH2 domain, while interaction of the SH3 domain of p130Cas with
the PR2 domain of FAK is needed for FAK-mediated p130Cas localisation at FA and subsequent
phosphorylation by Src. Nevertheless, the “Cas-family C-terminal homology” (CCH) domain may
adopt a tertiary structure similar to the FAT domain of FAK and recently it was demonstrated that
this CCH domain have the ability to function as a FA targeting domain [133]. Another candidate for
p130Cas targeting to FAs is the LIM protein Ajuba, which associates with the CCH domain of p130Cas
and may localize p130Cas to nascent adhesive sites in migrating cells [134]. Therefore, from these
data, it appears that p130Cas localize to FA via both FAK dependant and independent mechanisms,
although the main one at least in FAK-expressing cells, seems to be linked to the interaction of the SH3
domain of p130CAS with the PR2 of FAK. The activation of p130Cas is linked to both Rac-mediated
lamellipodia formation and subsequent increase migration and to transduction of ECM stiffness
into intracellular stiffness leading to an increase in cyclin D1 expression thereby modulating cell
cycling [135]. In v-Src-transformed cells, this pathway has also linked MMP expression and cell
invasion [94]. In these cells, FAK was also shown to form a complex with Calpain and p42ERK thus
promoting FAK proteolysis and FA turn-over. This interaction is mediated by the PR2 domain of FAK
and is necessary for efficient targeting of Calpain to FAs [136].
Table 1. Proteins associating with the PR domains are shown.
Interactions at PR Domain References
Trio, Src, PI3K, p130CAS, Calpain [125–127,132,133]
Cortactin, MT1-MMP, Ambra, PSGAP [134,137–140]
Graf, ASAP1, IQGAP1, CDK5, Dynein [141–146]
Cortactin is another important protein that directly interacts with both FAK PR2 and PR3 domains
thereby being phosphorylated at its tyrosine sites Tyr 421 and Tyr 466 which leads to FA dynamic
regulation [147]. Cortactin is a major signalling component of the specialized matrix-degrading
organelles termed invadopodia. Despite its role in the signalling pathway regulating invasion, FAK is
generally not located at invadopodia [137,148,149] although it has been described in inavdopodia from
MCF10A-CA1 breast cancer cells [138]. Nevertheless, FAK may promote invasion via focalised matrix
degradation at FAs, a process that involves a complex comprising FAK, p130CAS and MT1-MMP.
This complex is formed by a direct interaction between FAK and MT1-MMP implicating both PR1
and PR2 domains [139]. In addition, FAK interact via its PR3 domain with Endophilin A1, a protein
implicated in endocytosis. This interaction promotes Src-dependent phosphorylation of Endophilin A1
leading to inhibition of Endophilin/Dynamin interactions thereby reducing endocytosis of MT1-MMP
which contributes to ECM degradation [140].
The shuttling of FAK in and away from FAs is crucial for FAK regulation of the migration/invasion
pathway driven in part by the spatial-temporal control of Src activity. In cancer cells, inhibition of FAK
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leads to altered Src trafficking via at least two major pathways. The first implies a relocation of Src
from FAs to invadopodia through its interaction with the FAK homologue Pyk2 leading to enhanced
matrix degradation [148]. The second pathway is engaged to maintain cell viability when the FAK/Src
pathway is severely compromised and involves c-Cbl-mediated autophagic targeting of Src [141].
The targeting of Src to autophagosomes is controlled by the autophagy regulator Ambra1 (Activating
Molecule in Beclin1-Regulated Autophagy) and requires Ambra-binding proteins such as Dynactin
1 and IFITM3 (Interferon-Induced Transmembrane protein 3) [142]. Nevertheless, in the presence of
FAK, Ambra bind to the FAK PR3 domain thereby controlling the spatial regulation of FAK/Src at
FAs. Indeed, a FAK P875A/P881A mutant with disturbed Ambra binding properties increases the
time-residency of FAK/Src at FAs leading to enhanced adhesion.
3.3.2. FAK as a Regulator of the Rho-GTPase Family
Other SH3-containing domains that interact with FAK involve critical regulators of the
Rho-GTPase family, which are important molecular switches that regulate cell motility. GTPase
activating proteins (GAP) and guanine-nucleotide exchange factors (GEF) bind to these domains to
regulate Rho, Rac or Cdc42. For example, the Rho regulator, implicated in cytoskeleton reorganisation,
termed PSGAP (Pleckstrin homology and the SH3 domain containing rhoGAP) has been shown to
also interact with FAK. This protein binds to a sequence located near Pro 859 in Pyk2 close to the FAT
domain and presumably to the equivalent PR3 sequence in the FAK structure, although this has not
been formally demonstrated [150]. The Graf protein (GTPase Regulator Associated with FAK) also
binds via its SH3 domain to the PR3 site to regulated actin organisation, a mechanism required for FAK
function in promoting haptotaxis motility [104]. The Arf GAP proteins are another family of regulators
that stimulate GTP hydrolysis bound to ADP-ribosylation factors (Arfs) thereby controlling membrane
trafficking and cytoskeletal organization. ASAP1, an Arf GAP protein containing SH3, ANK repeat and
PH domains localized at peripheral adhesions has been shown to contain an SH3 domain that binds
to FAK and translocates from FAs to dorsal ruffles to regulate the Actin cytoskeleton [143]. Finally,
the intracellular scaffold protein containing both IQ and GTPase-activating protein 1 motifs (IQGAP1)
was recently found to interact with FAK in MDCK cells under conditions promoting RhoA activation
thereby controlling FAs assembly [144]. Is not known whether this interaction is direct or not but one
possibility could be a direct interaction between the WW motifs of IQGAP1 and the PR motifs of FAK.
On the other hand, FAK associates with the guanine nucleotide exchange factor PDZ-RhoGEF
to modulate Rho/Rho kinase II signalling necessary for focal adhesion dynamic at the tail and
trailing edge retraction but the structural determinants of FAK required for this interaction were not
described [145]. Both PDZ-RhoGEF and LARG, a GEF containing a PH domain, can be phosphorylated
by FAK in response to thrombin, thereby enhancing the activation of Rho [151]. The cycle of
activation/inactivation of Rho family GTPases depend on the coordination of GEFs and GAPs.
As discussed here FAK is associated with the recruitment at FA and their phosphorylation of several
GEFs necessary for full RhoA activation but also with GAP proteins like Graf or PSGAP necessary
for RhoA inactivation. It is unknown why FAK via different motifs such as Tyr397, PR domain or
FAT domains interact with different GEF or GAP. However, it is very unlikely that FAK bind to these
molecules at the same time. It seems rather that FAK controls the spatial-temporal activation of GEFs
and GAPs to modulate cell contractility during the migration process.
3.3.3. Role of FAK Ser732
The effects induced by the phosphorylation of FAK at Ser 732, that is close to PR2 have been
addressed in several cell types. The first reports describe that FAK phosphorylation at this site is
important for microtubule organization and microtubule-dependant mechanisms such as nuclear
translocation, mitosis and neural cell migration [146,152]. Latter, CDK5-dependant FAK phosphorylation
at Ser732 specifically localized at the spindle microtubule was shown to be implicated in cancer cell
proliferation and migration. Of note this process appears independent of Integrin engagement [153].
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Besides, CDK5, the Rho-dependent kinase ROCK also directly phosphorylates FAK downstream of
VEGF signalling [154]. Finally, an interaction between Dynein, Paxillin and FAK reported in both mouse
endothelial and NRK cells was shown to involve FAK phosphorylation at Ser 732 [155].
3.3.4. Inhibiting the FAK PR Domain Binding to SH3-Containing Protein
At the moment, no PPI inhibitors targeting FAK interactions via its PR domains has been
developed. However, this strategy may be valuable as protein domains that bind proline-rich motifs are
frequently involved in signalling events. Indeed, for FAK, P878A/P881A mutation were associated to
decrease expression levels of markers for epithelial-mesenchymal transition in vivo in a mouse model
of human breast cancer which correlate with an inhibition of the FAK/Endophilin A2 interaction [156].
Thus, targeting such interactions with small molecules or peptide-based sequences may be of potential
interest for clinical applications. PR sequences typically contain a Pro-Xaa-Xaa-Pro motif, which folds
into a polyproline helix that bind to SH3, WW, GYF or EVH1 domain. The typical Kd of these domains
for their respective targets range over 1 to 500 µM which cannot be considered as high affinity. All these
domains recognize several residues within the core motif of PR domains. Often aromatic side chains of
the PR-binding domain recognize defined proline residues. Selectivity is therefore achieved via specific
interaction with core-flanking epitopes and exposed side chains on the surface of the PR domain called
epsilon determinants [157]. The determination of the precise characteristic of these critical interactions
using structure-based molecular modelling together with the screening of peptide libraries may help
the search of PPI targeting PR domains.
3.4. Major Interactions at the FAT Domain
3.4.1. FAK Binding to Paxillin and the Targeting to Focal Adhesions
The C-terminal domain of FAK interacts with several FA-associated proteins including Paxillin and
Talin [158–160], p130CAS [132,161], Grb2 [159,162], the p85α subunit of PI3K [130] and VEGFR-3 [163].
Furthermore, the C-terminal domain is both necessary and sufficient for FAK localization at FAs
and thus has been called the FAT domain (Focal Adhesion Targeting). Structurally this domain is a
four-helix bundle carrying two hydrophobic patches HP1 and HP2 that mediate interaction with the
LD2 and LD4 motifs on Paxillin [164–166] (Figure 4). Hence, targeting of FAK to FA has been shown
to be mediated primary by binding of FAK to Paxillin although alternative ways, such as binding to
Talin, have been described [160]. Classical models postulate that upon Integrin engagement to the
ECM, Talin and/or Paxillin are recruited to nascent adhesions via binding to the cytoplasmic tail of
Integrin. Indeed, early studies have shown that FAK interact with Talin within the FAT domain and,
because in-vitro association of Talin with the Integrin β1 cytoplasmic domain has been detected, it was
suggested that Talin may target FAK to FAs [160]. However, recently it was clearly demonstrated that
FAK acts upstream of Talin and recruits it via FAT binding functions to nascent adhesions, although
this mechanism does not take place for Talin recruitment at mature adhesions [167]. Studies using cells
from Paxillin knock-out mice or deletion of FAK-Paxillin binding sites revealed an essential role for
Paxillin in targeting FAK to FAs although it should be noted that some residual FAK localization at
FAs is frequently observed [168,169]. Moreover, overexpression of Hic-5 a Paxillin homologue that
also localized to FAs, sequestered FAK from Paxillin and thus reduced phosphorylation of Paxillin
and FAK. Therefore, Hic-5-mediated inhibition of cell spreading can be attributed to a competition
with paxillin for FAK and subsequent prevention of downstream FAK signalling [170]. Alternative
routes for FAK localization at FAs may involve the FERM domain of FAK which enables either FAK
interaction with the Arp2/3 complex or FAK targeting to membranes and further binding to PtdIns
(4,5) P2 at sites of Integrin activation thereby connecting FAK to nascent adhesions [59,70]. Other
proteins containing LD motifs have also been shown to bind to the FAT domain of FAK. This includes
the tumour suppressor DLT1 (deleted in liver cancer 1) which encodes a Rho-GAP catalytic domain
that negatively regulates Rho-GTPases [171] and the delayed rectifier Kv2.1 potassium channel which
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upon FAK interaction promotes polarized cell morphology and enhanced motility [172]. Interaction
between the FAT domain and the FERM domain of FAK has also recently been shown to be involved
in FAK dimerization and activation. Surprisingly, the FAT-FERM interactions seem further stabilized
by paxillin binding to FAT [65]. Moreover, beside the targeting of FAK to FAs and its subsequent
implication for adhesion and migration processes, the FAK-Paxillin interaction is also involved in the
regulation of mitotic spindle orientation, thus controlling tissue morphogenesis [173].
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The FAT domain is a four-helix bundle composed of helix α1, α2, α3 and α4. The hydrophobic patches
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Tyr925 and Ser910 are highlighted. The residues of the hinge domain located between helix α1 and
α2 important for FAK dimerization and phosphorylation of Tyr925 are coloured in green. Proteins
associating with the FAT domain are shown in the table.
3.4.2. FAK Phosphorylation at Tyr925
One important motif of the FAT domain is the Tyr925 phosphorylation site, which has been
identified as a Src-dependent process because its phosphorylation is significantly reduced in cells
expressing a kinase-defective mutant of Src [180]. Upon phosphorylation it creates a binding site for
the SH2 domain of the adaptor protein Grb2 with further activation of the MAP kinase pathway [159].
This pathway has been implicated in the control of VEGF expression in breast carcinoma cells and,
when inhibited by selective mutation of FAK at Tyr925, leads to reduced tumour growth in mouse
associated with impaired neo-vascularisation [181]. Via the FAK-Grb2 association, Grb2 was also
proposed to link FAK to PTPα promoting PTPα phosphorylation to control downstream Integrin
signalling [182]. In addition, phosphorylation of this site has been associated with activation of
the p130CAS/Dock180/Rac1 signalling pathway-mediated cell protrusion [93] which, at least in
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Src-transformed fibroblasts, leads to increased matrix metalloproteinase expression and activity and
thus to mechanisms underlying cell invasion [94]. Nevertheless, direct association of p130CAS to
FAK has been shown to be preferentially mediated by the p130CAS SH3 domain binding to the PR1
FAK domain as previously discussed. Thus, although Dock180 co-immunoprecipitates with FAK, it is
unlikely that Dock180 directly interacts with FAK but instead, Dock180 and p130CAS are rather part
of a signalling complex which includes FAK and Src. Therefore, the precise molecular interactions
leading to activation of this pathway upon phosphorylation of FAK Tyr925 remains to be elucidated as
is the search for other SH2-countaining proteins that could interact with this phosphorylated site.
Cell motility also requires the coordinated turnover of nascent adhesions at the leading edge and
the disassembly of FA at the rear, a process dependent upon FAK phosphorylation at Tyr925. Because
phosphorylation of Tyr925 and subsequent binding of SH2-containing protein require rearrangement
of the FAT structure, it has been suggested that this process would lead to alteration of FAK-Paxillin
interactions thus ultimately leading to FAK removal from FA [174]. However, although phosphorylation
of FAK at Tyr925 increases FA dynamic, it also contributes to increasing the time residency of FAK
at FAs and therefore may not be the molecular determinant necessary for FAK removal from FA [93].
On the other hand, rearrangement of the FAT domain involving opening of helix1 from the four-helix
bundle may be a conformational change triggering the removal of FAK from FAs. Indeed, this structural
rearrangement would alter the conformation of the hydrophobic patch HP2 thus reducing FAK-Paxillin
interaction and also allow easy access to Tyr925 for kinase-mediated phosphorylation and subsequent
binding of SH2-containing proteins. Indeed, selective deletion of Q943/A945 in the FAT domain of
FAK, aimed at inducing increased strain generated by the prolines in the H1-H2 hinge region leads
to an increased probability of helix 1 opening as observed by decrease FAK-Paxillin interaction and
increase phosphorylation at Tyr925 [175]. Nevertheless, the nature of the signal leading to opening of
the FAT domain and subsequent phosphorylation at Tyr925 remains to be determined.
3.4.3. FAK Phosphorylation at Ser910
Early studies have shown that agonists of G protein-coupled receptors, including Bombesin and
lysophosphatidic acid stimulate FAK phosphorylation at Ser910, through an ERK-dependent pathway.
Moreover, growth factors that stimulate the ERK pathway in 3T3 fibroblast, like FGF, phosphorylate
FAK at Ser910 whereas others like Insulin which is unable to simulate the ERK pathway does not
promote FAK phosphorylation at Ser910 further indicating the requirement of ERK for phosphorylation
at this site [176,183]. Interestingly, phosphorylation of Ser910 in response to Bombesin was increased
in a tense FAK mutant with deletion at Q943/A945 that induces destabilization of the FAT domain
suggesting that FAT rearrangement also increases Ser910 accessibility to Ser/Thr kinases [175]. Ser910
is located just before a proline rich domain containing P911/P912/P913. Typically, proline-rich domains
that binds to SH3 or WW containing proteins are composed of a Pro-X-X-Pro motif but a subset of WW
domain bind specifically to pSer/Thr-Pro motifs. The enzymes responsible for the phosphorylation
of Ser/Thr-Pro motifs are Pro-directed protein kinases, a large family of kinases which include for
example MAPKs, GSK-3 and JNKs. Proline residues exist in both cis and trans isomers catalysed by
peptidyl–prolyl cis/trans isomerases. A specific peptidyl–prolyl cis/trans isomerases of the Parvulin
family called PIN1 (protein interacting with NIMA1) catalyses the isomerization of Ser/Thr-Pro motifs
once phosphorylated. Recently it was shown that the phosphorylation of FAK at Ser910 enables the
binding of PIN1thus leading to the recruitment of a protein tyrosine phosphatase PTP-PEST. This in
turn leads to the dephosphorylation of FAK at Tyr397 [177]. Therefore, surprisingly in this study
the inhibition of FAK via dephosphorylation at Tyr397 is linked in Ras-transformed fibroblast to the
ability of Ras to induce cell migration, invasion and metastasis. Considering the overall data indicating
a positive role of FAK in tumour progression, the authors suggest that FAK is required for tumour
development induced by oncogenic proteins which activate a positive FAK/Src feedback loop whereas
in tumour with aberrant Ras which do not rely on Src for their oncogenic development, a MAPK
pathway leading to reduce FAK activity is activated that promote invasion and metastasis.
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3.4.4. FAK as a Regulator of the Rho-GTPase Family
We described previously interactions between Rho-GTPase family regulators with proline-rich
domains of FAK but FAK also interacts via its FAT domain with some of these regulators. First,
as discussed before, FAK interacts directly or via formation of a complex that include p130Cas,
with Dock180, a GEF for Rac thereby promoting lamellipodia formation. FAK also regulate Rho via
interaction with p190RhoGEF that stimulate Rho activity. Although the interaction domains were not
precisely mapped, mutation of FAKL1034S, which destabilizes the four-helix bundle of the FAT domain,
disrupts FAK interaction with p190RhoGEF thus clearly indicating the requirement for an intact FAT
domain [178]. Another protein called GIT1, for G-protein-coupled receptor kinase (GRK)-interacting
targets which contains at the N terminal a motif functioning as Arf GAP was found to directly
associate with FAK via a region closely related to the yeast Spa2 homology domain 1 (SHD-1) [184].
GIT1 is a multifunctional protein involved in focal complex disassembly able to bind Paxillin and the
PAK/β-PIX complex (p21-activated kinase/PAK-interacting exchange factor PIX). PAK is an effector
for Rac1 and Cdc42 whereas β-PIX is a GEF for Rac. GIT1, like FAK, encompass Paxillin binding
motifs that allow direct interaction with the LD4 motif of Paxillin, supporting the notion that GIT1
may regulate FAK/Paxillin interactions and thus focal complex dynamics. Moreover, in NIH3T3 cells,
lysophosphatidic acid-induced GIT1-dependent β-PIX binding to FAK thereby involving FAK to both
the control of lamelipodia formation via Rac activation and focal complex dynamic via regulation of
FAK/Paxillin binding [179]. Nevertheless, the precise role of FAK in this regulation pathway leading
to cell polarity and directional migration is even more complex. Indeed, phosphorylation of GIT1
by the FAK/Src complex is required for GIT1 association with FAK at FAs [185]. On the other hand,
phosphorylation of GIT2, also called PKL for paxillin kinase linker, by the same FAK/Src complex
in response to platelet derived growth factor (PDGF) stimulation, is required for GIT2 association
with Paxillin and control of wound-induced cell polarization as well as directional migration [186].
Another regulator of cell polarization and directional migration is Eps8 (Epidermal growth factor
receptor kinase substrate 8), initially described as a substrate for EGFR involved in the Ras signalling
pathway and endocytosis. In squamous cell carcinoma, Eps8 interacts with FAK at FAs and is required
for FAK-dependent polarization and invasion [187]. This interaction require binding of Eps8 to the
FAT domain of FAK spanning the region of the amino acids 981–1053, whereas in the absence of FAK,
Eps8 interacts with Src to control its trafficking to autophagic structures. These findings demonstrate
complex mechanisms by which FAK can function in the regulation of Rac, Rho and Cdc42 to control
cellular polarization, lamellipodia extension and directed migration.
3.4.5. Inhibitors of FAT Interactions
FAK localisation at FA is essential for its regulation by Integrin signalling as demonstrated using
replacement of the FAT sequence of FAK [188]. Historically, the first inhibitor of FAK described was
the endogenous and autonomously expressed inhibitor FRNK (Focal adhesion kinase-Related Non
Kinase) [189]. Indeed, early experiments using FRNK, indicated that many aspects of FAK function,
especially adhesion and migration, involve FAK targeting to FAs [190,191]. Therefore, one way to
inhibit FAK function in cancer cells would be to interfere with this targeting at the level of FAT.
However, it was recently shown that FRNK inhibits growth and survival by direct binding to FAK in
an inhibitory complex. This inhibition could be relieved by phosphorylation of FRNK at S217 which is
the analogue of Ser910 for FAK [192]. Nevertheless, recently it was observed that altering FAK/Paxillin
interactions via specific mutations in the FAT domain reduce adhesion and migration processes in
non-cancer cells while inhibiting invasion in Src-transformed mouse fibroblasts [193]. Interestingly,
the reduced capability of adhesion, migration and invasion observed in cells lacking FAK targeting
to FA was greater to complete FAK knock-out demonstrating a gain of function which might be due
to an unexpected ability of the mutated form of FAK to sequester key binding partners outside FAs.
Thus, development of molecules targeting FAK interaction with protein involved in the localisation of
FAK at FAs, may be a valuable strategy for the search of novel FAK inhibitors. A successful illustration
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of such a strategy came from William Cance’s group who reported that the FAT domain of FAK is also
able to bind to VEGFR-3 in different cancer cell types. They further mapped this interaction to a region
containing amino acid 853-1052 of FAT. Inhibiting this interaction with a peptide derived from the
VEGFR-3 sequence coupled to a TAT cellular penetration motif decrease cell proliferation and induces
apoptosis in breast cancer cells [163]. Going a step forward by using the crystal structure of FAT for
molecular docking of small compounds targeting the site of interaction with VEGFR-3, they found
that chloropyramine hydrochloride, a small molecule previously reported as a H1 histamine receptor
antagonist, were able to alter FAK/VEGFR-3 interaction. This led to inhibition of cell proliferation
in-vitro and reduction of tumour growth in-vivo in mice bearing breast cancer cell xenografts [194].
Once the lead compound had been validated, they further designed and synthesised analogues of
this compound to be tested for binding to FAT and anti-cancer activities. From this second screening,
analogue 29 was found to show enhanced specificity and selectivity for FAK-VEGFR-3 interaction
and display in-vitro anti-tumour effect in a variety of cancer cell lines including pancreatic and breast
cancer cell, glioma and melanoma [195].
4. Conclusions
Successful examples have now proven the efficiency of PPI inhibitors as some of these already
reached clinical trials. FAK is at the crossroads of integrin and growth factors signalling and, as FAK is
overexpressed in many human cancers, FAK is frequently associated with the promotion of oncogenic
signals and the inhibition of tumour suppressive pathways. This makes FAK a clearly interesting
cancer target. The development of PPI inhibitors targeting FAK is thus quite promising as FAK,
via several specific subdomains and numerous sites of phosphorylation, is at the heart of an important
interactome. Several small molecules targeting FAK kinase function are currently being developed
with some success in clinical trials. Especially, targeting FAK in combination with therapies against
other signalling pathways may be a promising approach for the treatment of drug-resistant cancers.
Therefore, with the mapping of many FAK interactions at the molecular level, the search for inhibitors
of FAK scaffolding function may lead to new promising therapeutics.
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